Table IV.
Studies exploring the expression and clinical significance of SIRT1, RORA and TIM in patients with CRC.
| Author, year | Gene | Expression in CRC | Observations | (Refs.) |
|---|---|---|---|---|
| Pazienza, 2012 | SIRT1 | Decreased | Not specified | (94) |
| He, 2022 | RORA | Decreased | Not specified | (37) |
| Gu, 2018 | RORA | Decreased | Not specified | (93) |
| Mazzoccoli, 2011 | TIM | Upregulated | High TIM levels were associated with MSI and proximal lymph nodes, and were prevalent in TNM stages III-IV | (39) |
| Colangelo T, 2022 | TIM | Not mentioned | Loss of TIM expression is associated with advanced tumor stage, metastasis and microsatellite stability status; TIM expression was inversely correlated with a set of EMT marker genes | (95) |
| Xue, 2014 | NPAS2 | Decreased | Low expression of NPAS2 was associated with tumor size, TNM stage and metastasis | (96) |
CRC, colorectal cancer; MSI, microsatellite instability; EMT, epithelial to mesenchymal transition; NPAS2, neuronal PAS domain protein 2; TIM, timeless; SIRT1, sirtuin1; ROR, retinoic acid receptor-related orphan receptor.